{
  "2847593_syn_1": "Procedure: EBUS-TBNA & Ion Robotic Bronchoscopy.\nEBUS: Stations 4R, 7 sampled. Positive for Adeno.\nIon: Navigated to RLL mass. r-EBUS concentric. Biopsied x8.\nROSE: Adenocarcinoma in node and mass.\nDx: Stage IIIA (N2 positive).",
  "2847593_syn_2": "OPERATIVE NARRATIVE: A combined staging and diagnostic procedure was performed. First, convex EBUS allowed for sampling of stations 4R and 7; rapid on-site evaluation demonstrated adenocarcinoma. Subsequently, the Ion robotic platform was docked. The catheter was navigated to the RLL posterior basal segment mass. Radial EBUS confirmed concentric alignment. Transbronchial biopsies were obtained. The pathologic findings confirm primary lung adenocarcinoma with mediastinal nodal involvement (N2 disease).",
  "2847593_syn_3": "Codes:\n- 31652 (EBUS-TBNA 1-2 stations): Sampled 4R, 7.\n- 31628 (Transbronchial lung biopsy): RLL mass via Ion.\n- 31627 (Navigational Bronchoscopy): Ion system used.\n- 31654 (Radial EBUS): Peripheral lesion check.\nNote: Nodal staging performed first.",
  "2847593_syn_4": "Resident Note\nPt: [REDACTED]roc: EBUS + Ion\nSteps:\n1. EBUS first. Biopsied 4R and 7. Both malignant.\n2. Switched to Ion robot.\n3. Navigated to RLL mass.\n4. rEBUS showed we were in the lesion.\n5. Took biopsies.\nImpression: Stage 3 Lung Cancer.",
  "2847593_syn_5": "We did a combined case today EBUS and the robot. Started with EBUS sampled the 4R and 7 nodes both looked cancerous on the slide. Then used the Ion robot to go out to that mass in the right lower lobe. Navigation was smooth. Biopsied the mass too confirmed it was the same cancer. So she has stage 3A.",
  "2847593_syn_6": "Combined endobronchial ultrasound and robotic navigational bronchoscopy. Mediastinal staging was performed first via EBUS-TBNA of stations 4R and 7, revealing metastatic adenocarcinoma. The Ion robotic system was then utilized to navigate to a right lower lobe mass. Radial EBUS confirmed target acquisition. Transbronchial biopsies of the mass also showed adenocarcinoma. The patient was extubated and transferred to recovery.",
  "2847593_syn_7": "[Indication]\nRLL mass, mediastinal adenopathy.\n[Anesthesia]\nGeneral, ETT.\n[Description]\n1. EBUS-TBNA: 4R, 7 positive for malignancy.\n2. Ion Robotics: Navigation to RLL mass. Biopsies positive for malignancy.\n[Plan]\nOncology consult for Stage IIIA NSCLC.",
  "2847593_syn_8": "[REDACTED] a diagnostic bronchoscopy today. We started by checking the lymph nodes in the center of her chest using the EBUS scope. Unfortunately, the samples from nodes 4R and 7 showed cancer cells. We then used the robotic system to navigate to the main tumor in her lower right lung and took a biopsy of that as well, which matched the lymph nodes. This confirms the cancer has spread to the lymph nodes, placing her at Stage IIIA.",
  "2847593_syn_9": "Procedure: Endosonography and Robotic-assisted bronchoscopy.\nFindings: Mediastinal nodes 4R and 7 were sampled and found malignant. The primary RLL lesion was accessed via the robotic platform and sampled.\nConclusion: Primary adenocarcinoma with nodal metastasis.",
  "2847593": "**INTERVENTIONAL PULMONOLOGY PROCEDURE REPORT**\n\n**PATIENT INFORMATION:**\nName: [REDACTED]nne\nMRN: [REDACTED]\nDOB: [REDACTED]\nSex: Female\nDate of Service: [REDACTED]\n\n**CLINICAL TEAM:**\nAttending: Dr. Nicholas Foster, MD, FCCP\nFellow: Dr. Amy Chen, MD\nAnesthesia: Dr. Robert Martinez, MD\nNursing: RN Jessica Thompson\nRespiratory Therapy: RT Michael Davis\n\n**PROCEDURES PERFORMED:**\n1. Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA)\n2. Ion robotic navigational bronchoscopy\n3. Radial endobronchial ultrasound\n4. Transbronchial biopsy\n\n**CPT CODES:** 31652, 31653, 31627, 31654, 31628\n\n**INDICATIONS:**\n55-year-old female with 35 pack-year smoking history presents with:\n- Right lower lobe mass, 3.4cm, PET SUV 9.2\n- Mediastinal lymphadenopathy: Station 4R (2.1cm, SUV 5.8), Station 7 (1.8cm, SUV 4.3)\n- Requires both nodal staging and peripheral mass biopsy for diagnosis and treatment planning\n\n**CONSENT:**\nComprehensive informed consent obtained. Risks discussed including but not limited to: bleeding (1-5%), pneumothorax (1-3%), infection (<1%), mediastinal complications (pericardial/vascular injury <0.1%), need for additional procedures, anesthesia-related complications. Patient expressed understanding and agreed to proceed.\n\n**ANESTHESIA:**\nGeneral endotracheal anesthesia administered.\n- Induction: Propofol 200mg, Fentanyl 150mcg, Rocuronium 50mg\n- Maintenance: Sevoflurane, intermittent propofol boluses\n- ETT: 8.0mm at 22cm at teeth\n- Ventilation: Pressure control, Pinsp 18, RR 12, PEEP 5, FiO2 50%\n\n**PRE-PROCEDURE TIMEOUT:**\nPerformed confirming patient id[REDACTED] (verbal + 2 id[REDACTED]), procedure planned, site/laterality confirmed, team introductions, equipment availability checked.\n\n**PROCEDURE NARRATIVE:**\n\n**PHASE 1: EBUS-TBNA FOR MEDIASTINAL STAGING**\n\nEBUS bronchoscope (Olympus BF-UC190F) introduced through ETT.\n\nSystematic mediastinal lymph node survey performed:\n\n**STATION 4R (Right paratracheal):**\n- Size: 22mm x 14mm\n- Ultrasound features: Hypoechoic, heterogeneous, discrete borders\n- Vascular pattern: Central hilar vessels present\n- Elastography: Predominantly hard (strain ratio 8.2, suggesting malignancy)\n- TBNA: 22-gauge needle, 4 passes\n- ROSE: \"Abundant cellularity, malignant cells present, consistent with non-small cell carcinoma, favor adenocarcinoma\"\n\n**STATION 7 (Subcarinal):**\n- Size: 19mm x 16mm\n- Ultrasound features: Hypoechoic, round, sharp borders\n- Elastography: Firm (strain ratio 6.8)\n- TBNA: 22-gauge needle, 4 passes\n- ROSE: \"Similar malignant cells as 4R, adenocarcinoma\"\n\n**Additional Stations Surveyed but Not Sampled:**\n- Station 10R: 8mm (below size threshold)\n- Station 11R: 6mm (not sampled - diagnostic yield from 4R/7 adequate)\n- Left-sided stations: No enlarged nodes id[REDACTED]\n\n**PHASE 2: ION ROBOTIC BRONCHOSCOPY FOR RLL MASS**\n\nAfter completing EBUS, EBUS scope removed. Ion robotic bronchoscope introduced.\n\n**Navigation Setup:**\nCT chest from [REDACTED] loaded to Ion platform. 3D reconstruction showed target in RLL posterior basal segment.\n\n**Ion Registration:**\nAutomatic registration performed. Landmarks matched at carina, RLL carina, and segmental bifurcations. Mean fiducial error: 1.3mm (acceptable). No registration drift observed.\n\n**Navigation to Target:**\nIon catheter advanced under navigational guidance to RLL posterior basal segment. Real-time tracking showed tool-to-target distance of 0.7cm at final position.\n\n**Radial EBUS:**\n20MHz probe inserted through Ion extended working channel.\n- Pattern: Concentric (lesion centered around probe)\n- Size: 32mm diameter\n- Characteristics: Heterogeneous echogenicity, irregular margins, no visible vessels in immediate vicinity\n\n**CBCT Confirmation:**\nCone-beam CT spin acquired. NaviLink 3D fusion overlay confirmed catheter tip within lesion borders, 4mm from lesion center.\n\n**Sampling of RLL Mass:**\n- Transbronchial biopsies: 8 specimens obtained via Ion catheter\n- Cytology brushings: 3 specimens\n- Bronchial washing: sent for cytology and microbiology\n\n**ROSE (Peripheral Lesion):**\n\"Adequate samples. Malignant cells consistent with adenocarcinoma, morphologically similar to lymph node specimens. Recommend molecular testing.\"\n\n**HEMOSTASIS:**\nNo significant bleeding from any biopsy sites. Airways clear.\n\n**PROCEDURE COMPLETION:**\nTotal procedure time: 78 minutes\nEBUS portion: 32 minutes\nIon bronchoscopy portion: 46 minutes\n\nPatient [REDACTED] well. Extubated in OR without difficulty. Transferred to PACU in stable condition, SpO2 98% on 2L NC.\n\n**ESTIMATED BLOOD LOSS:** <10mL\n\n**SPECIMENS:**\n1. Station 4R TBNA x 4 passes (cell block + cytology)\n2. Station 7 TBNA x 4 passes (cell block + cytology)\n3. RLL mass TBBx x 8 (formalin, histopathology - **ORDER MOLECULAR TESTING**)\n4. RLL mass brushings x 3 (cytology)\n5. RLL mass washing (cytology, bacterial/fungal/AFB cultures)\n\n**COMPLICATIONS:** None\n\n**PRELIMINARY FINDINGS:**\n- N2 disease confirmed (stations 4R, 7 both positive for adenocarcinoma)\n- Primary RLL adenocarcinoma confirmed\n- Stage: At least IIIA (T2bN2M0) pending full staging workup\n\n**POST-PROCEDURE PLAN:**\n1. Recovery room monitoring per protocol\n2. Chest X-ray in 2 hours to rule out pneumothorax\n3. Discharge home same day if stable and CXR clear\n4. Complete staging: Brain MRI, consider bone scan if not covered by PET\n5. Molecular testing: EGFR, ALK, ROS1, BRAF, PD-L1, broader NGS panel\n6. Multidisciplinary tumor board presentation next week\n7. Medical oncology referral for neoadjuvant therapy discussion\n8. Radiation oncology consultation\n9. Follow-up in IP clinic in 1 week with full pathology results\n\n**CLINICAL IMPRESSION:**\nStage IIIA adenocarcinoma of the lung (RLL primary with N2 mediastinal involvement). Not a surgical candidate initially. Will likely require neoadjuvant chemoimmunotherapy with consideration for surgery after response assessment vs definitive chemoradiation. Molecular profiling pending.\n\n**ATTENDING STATEMENT:**\nI was present throughout the entire procedure, personally performed the critical portions including EBUS-TBNA and supervised the Ion navigation and sampling. I reviewed all ROSE results in real-time and made all clinical decisions.\n\nElectronically signed: Dr. Nicholas Foster, [REDACTED] 16:42"
}
